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Neoplasm metastasisProstatic ductal adenocarcinoma is an uncommon form of prostatic carcinoma.We report a case of a 63-year-old
man who presented with non-infective thrombotic (marantic) endocarditis and an incidental ﬁnding of a de-
structive lesion in the left iliac crest. Core biopsy of the lesion showed a carcinoma with papillary architecture
and was initially diagnosed as “metastatic carcinoma of unknown origin”. The patient experienced a cerebral in-
farction and expired six days later. Postmortem examination revealed extensive mixed acinar and ductal adeno-
carcinoma (Gleason score 5 + 4 = 9) in the prostate. Further studies conﬁrmed the bone lesion as metastatic
prostatic ductal adenocarcinoma. Although rare, metastatic prostatic adenocarcinoma should be considered in
the differential diagnosis in a male patient when the carcinoma shows predominantly papillary architectures.
A review of literature is presented to enhance the awareness of this entity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostatic ductal adenocarcinoma (PDA) is uncommon, accounting
for about 0.4–0.8% of prostate cancers [1–3]. Few studies of metastatic
PDA have been reported [4]. In contrast to the more common acinar
type carcinoma which is composed of cuboidal cells arranged in acini,
PDA is histologically characterized by papillary or cribriform architec-
tures lined by tall columnar cells with abundant cytoplasm and
pseudostratiﬁcation. PDA can be found in isolation; however it is most
commonly admixedwith themore typical acinar type prostatic carcino-
ma. Mixed PDA-acinar type carcinoma is reported in 5% of prostate car-
cinomas [2,5]. PDA is generally associated with a poor prognosis [3,6,7],
and has a propensity to metastasize to the penis, testis, bone, liver,
lungs, and brain [2,4,5,8]. Metastatic PDA typically shows papillary or
cribriform patterns which can cause diagnostic difﬁculty because the
cytologic and histologic features do not clearly reveal a prostatic origin.
Papillary or cribriform architecture can be found in metastatic carcino-
mas arising from many other organs such as the gastrointestinal tract,
pancreaticobiliary tract, lung, kidney, thyroid, and urinary bladder [4].
Given the rarity of this tumor and its overlapping morphologicals case report.
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. This is an open access article undercharacteristics with other carcinomas, diagnosis of a metastatic PDA
on a core biopsy can be challenging. As the clinical behavior of PDA is
more aggressive, it is imperative to accurately diagnose this entity [9].
We describe herein a case of metastatic prostatic ductal adenocarcino-
ma in a 63-year-old man which was diagnosed only upon postmortem
examination. Review the relevant literature on this rare entity is
provided.
1.1. Case history
A 63-year-old Caucasian man with a past medical history of hyper-
tension and coronary artery disease presented with bilateral lower ex-
tremity claudication, and was diagnosed with bilateral deep vein
thrombosis. He was treated with systemic anticoagulation and
discharged home. Threeweeks later, he presentedwith acute dysphagia
and dysarthria; brain imaging demonstratedmultiple acute cerebral in-
farctions. He subsequently showed signiﬁcant neurological recovery.
Ten days later, however, he developed bilateral lower extremity ische-
mia requiring embolectomies and a right below-the-knee amputation.
Further workup included a transthoracic echocardiogram which re-
vealed bilateral mitral leaﬂet mobile masses consistent with endocardi-
tis. Multiple blood, sputum, and urine cultures were negative for
bacterial or fungal growth during his hospitalization. The patient was
diagnosed with non-infective thrombotic (marantic) endocarditis. A
CT scan of the abdomen unexpectedly revealed a 3 × 2 cm lytic lesion
in the left iliac bone concerning for malignancy (Fig. 1A). A core biopsythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. The iliac bone lesion. A, CT scan showed a 2 × 3 cm destructive lesion of left iliac bone eroding through the cortex and into the surrounding soft tissue. B, Core biopsy of the bone
lesion showed a metastatic carcinoma composed predominantly of papillary architecture with focal cribriform areas, lined by a single layer of cuboidal to low columnar tumor cells, with
edematous to sclerotic ﬁbrovascular cores (H&E, original magniﬁcation ×200).
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agnosed as “metastatic carcinoma of unknown origin” (Fig. 1B). Serum
prostatic speciﬁc antigen (PSA) was not tested, nor was there a prior
prostatic biopsy. The patient continued to experience embolic events in-
cluding numerous cerebral infarcts, was transitioned to hospice care,
and expired six days after the core biopsy. The clinical causes of death
were respiratory failure, cardiac arrest, stroke and embolic events. His
family consented to a complete autopsy.
1.2. Core biopsy ﬁndings
An antemortem core biopsy of the left iliac bone lesion was per-
formed under CT guidance. The histological sections demonstrated an
epithelial lesion composed predominantly of papillary architecture
with focal cribriform patterns, lined by single layer of cuboidal tumor
cells with crowded, round-to-ovoid hyperchromatic nuclei and abun-
dant eosinophilic cytoplasm (Fig. 1B). A broad differential was consid-
ered including papillary renal cell carcinoma, papillary thyroid
carcinoma, papillary urothelial carcinoma, papillary lung carcinoma,
mesothelioma, and an unusual type of carcinoma of the digestive sys-
tem. Immunohistochemical stain demonstrated positive staining for
AE1/AE3 and EMA, and negative staining for vimentin, CK7, CK20,
CD10, GATA3, PAX8, calretinin, and WT1. The case was signed out as
“metastatic carcinoma of unknown origin.”
1.3. Autopsy ﬁndings
Upon postmortem examination, there was no evidence of mass le-
sion in the kidneys, bladder, thyroid, lungs, gastrointestinal tract, pan-
creas, liver, pleura, or peritoneum. The prostate was diffusely enlarged
(4.5 × 4 × 4 cm) and bulky with a tan-yellow nodular parenchyma.
The left iliac bone lesionwas identiﬁed, whichwas a 3 × 2 × 2 cm irreg-
ular, soft, red-brown lytic lesion Initial sections of prostate revealed ex-
tensive prostatic acinar adenocarcinoma, Gleason score of 5 + 4 = 9
(Fig. 2A). The bone lytic lesion revealed metastatic carcinoma with a
pure PDA pattern showing numerous papillae with overlying high
grade epithelium composed of cuboidal to low columnar cells with
glands showing focal cribriform architecture. Themorphology was sim-
ilar to prior biopsy (Fig. 2C). A panel of immunostains was performed,
and both the prostatic carcinoma and metastatic carcinoma in the
bone were positive for prostate-speciﬁc acid phosphatase (PSAP,
Fig. 2D) but negative for PSA. In addition, the metastatic carcinoma
was also positive for NKX3.1 and P501S (Fig. 2E and F). Additional sec-
tions of the prostate showed a minor portion of carcinoma withpapillary and cribriform architecture, similar to the metastatic tumor,
which further conﬁrmed the diagnosis ofmetastatic prostatic ductal ad-
enocarcinoma in the bone (Fig. 2B). Approximately 10% of tumorwithin
prostate showed PDA features with the remaining 90% of the tumor
showing high grade acinar-type morphology. Extraprostatic extension
and seminal vesicle invasion was also present.
Other signiﬁcant autopsy ﬁndings included nonbacterial thrombotic
(marantic) endocarditis of the mitral valve, three vessel atherosclerotic
coronary artery disease, multiple thromboemboli in the superior mes-
enteric artery and bilateral small renal arterial branches, multiple cere-
bral infarctions, infarctions of right lower of the lung, small and large
bowel, spleen, prostate, and renal cortex. The cause of death was com-
plications of metastatic prostatic adenocarcinoma.2. Discussion
Prostate cancer is the second most common cancer and the sixth
leading cause of cancer-related death in males worldwide [10]. The
vast majority of prostate carcinomas are of the acinar type in which
75–80% arise in the peripheral zone and are histologically characterized
by cuboidal cells arranged in acini. Prostatic ductal adenocarcinoma
(PDA) is a relatively rare variant of prostate cancer. PDA is diagnosed
in its pure form in 0.4–0.8% of prostatemalignancies [1–3,5]. More com-
monly, PDA is admixed with more typical acinar type adenocarcinoma
in up to 5% of prostate carcinomas [2,5]. Prostatic ductal carcinoma, ini-
tially described byMelicow and Pachter in 1967, was originally believed
to be a malignancy derived from remnant paramesonephric tissue. Due
to its histologic similarity to uterine endometrial carcinoma, it was
given the name “endometrioid” carcinoma [11]. Further ultrastructural
and histochemical studies aswell as positive response to androgen dep-
rivation showed these tumors are derived from prostatic ductal epithe-
lial tissue and thus renamed prostatic ductal adenocarcinoma
[1–6,8,12].
PDA commonly arises in the large primary periurethral ducts and is
clinically associated with a gross hematuria and urinary obstructive
symptoms [2]. As PDA typically forms in a periurethral location, digital
rectal examination has poor sensitivity in diagnosing this tumor [13].
PDA often shows exophytic growth into the prostatic urethra with in-
volvement of the verumontanum [5]. PDA can also arise in the smaller
peripheral zone prostatic ducts, which is typically diagnosed by needle
biopsy [13,14]. Serum prostate speciﬁc antigen (PSA) is variable in duc-
tal adenocarcinoma and often not predictive of ﬁndings upon radical
prostatectomy [6,15].
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Fig. 2. Findings at autopsy. A, Prostatic adenocarcinoma predominantly showed Gleason 5 pattern. B, Prostatic adenocarcinoma focally with papillary architecture, consistent with ductal
adenocarcinoma. C, Metastatic carcinoma in the iliac bone lesion, morphologically similar to prior biopsy (Fig. 1B) and the prostatic ductal adenocarcinoma (Fig. 2B). D–F,
Immunohistochemical study showed that the metastatic carcinoma in the iliac bone was positive for PSAP, NKX3.1, and P501S. (original magniﬁcation ×400).
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[16]. While typical acinar type carcinoma is characterized by acini
lined by a simple cuboidal epithelium, a common histologic feature of
PDA is pseudostratiﬁed, tall, columnar epithelium [6]. The cells typically
contain abundant amphiphilic cytoplasmwhich can bepale or clear. The
nuclei are large, elongated, with a variably prominent nucleolus and a
greater degree of chromatin irregularities and hyperchromasia when
compared to acinar carcinoma. Mitotic ﬁgures are present at a higher
rate than that seen in acinar carcinoma [3,6,8]. Seipel et al. investigated
the interobserver variability of the diagnosis of PDA among 20 expert
urologic pathologists. For 11 consensus cases of PDA, the histologic fea-
tures reported to bemost important were papillary architecture (86% of
responses), followed by nuclear stratiﬁcation (82%), high grade nuclear
featureswith prominent nucleoli (54%), tall columnar epithelium(53%),
elongated nuclei (52%), cribriform architecture (40%), and necrosis (7%)
[17]. The antemortem core biopsy of this patient's left iliac bone lesion
showed a single layer of predominately non-stratiﬁed cuboidal epitheli-
um which is atypical for PDA. The papillary structures and focal cribri-
form architecture, however, provide an important clue to a possible
prostatic origin and should have led to immunohistochemical evalua-
tion with prostatic markers including PSA, PSAP, androgen receptor, or
NKX3.1. In addition, regardless of morphology, prostate carcinoma
should always be considered in the differential diagnosis for metastatic
carcinoma to bone in middle aged to elderly men.
PDA can show various architectural patterns including papillary,
cribriform, individual gland, solid, and the more recently characterized
“prostatic intraepithelial neoplasia-like”morphology. Multiple patterns
can be presentwithin a single tumor [9,18]. Themost common patterns
are papillary and cribriform [6,13]. The papillary pattern, a distinct ar-
chitecture not seen in usual acinar carcinoma, consists of true papillary
fronds lined by crowded pseudostratiﬁed columnar cells with a variablenuclear pleomorphism and hyperchromasia. The papillae are complex,
branching and often fused [19]. The cribriformpattern, being somewhat
similar in appearance to endometrioid adenocarcinoma, is the reason
for these tumors being initially referred to as “endometrioid carcinoma
of the prostate” [13]. The cribriform pattern consists of enlarged, back-
to-back cribriform glands containing multiple lumina separated by cell
bridges. The lumina are lined by tall, pseudostratiﬁed columnar cells
with elongated hyperchromatic nuclei. The cribriform glands often
show central necrosis. In both papillary and cribriform architectures,
the background stroma typically shows prominent desmoplasia and/
or ﬁbrosis [2,6,20]. The “individual gland” pattern is characterized by
single glands with a malignant-appearing pseudostratiﬁed tall colum-
nar epithelium, resembling adenocarcinoma of the colon [13,21]. A
solid pattern has been described where the malignant cells proliferate
in solid nests or cribriformglands showing central necrosis,which is dif-
ﬁcult to distinguish from poorly differentiated acinar carcinoma [13].
Practically in all cases, the cells of PDA are at least focally PSA or PSAP-
positive. Seventy-seven percent of PDA stain positive for AMACR, and
the predominance of cases is negative for p63 or HMWCK (34βE12).
However, a study by Herawi and Epstein showed 31% of cases have
patchy detectable basal cells by p63 or HMCK (34βE12) [22]. The
newer prostatic markers such as P501S and NKX3.1 are also shown to
be positive in both ductal adenocarcinoma and high-grade acinar carci-
nomas of the prostate [23–25].
A needle biopsy study by Brinker et al. in 1999 suggested that surgi-
cally resected cases of PDA had a prognosis between that of Gleason
score 7 and Gleason score 8 acinar carcinoma [6]. Therefore, the current
consensus is to treat cases of pure ductal adenocarcinoma as Gleason
score 4 + 4 = 8; however the presence of comedonecrosis justiﬁes in-
creasing to Gleason grade 5. In mixed ductal and acinar adenocarcino-
ma, ductal component is assigned Gleason pattern 4 (or 5 if
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arately [13,26]. Themajority of studies show PDA to bemore aggressive
than acinar carcinoma with a more advanced clinical and pathologic
stage at presentation, and a worse 5 year survival rate. Studies have
shown PDA to be less responsive to traditional hormonal, radiation,
and radical surgical therapies [3,5–7]. When diagnosed on needle biop-
sy, greater than 50% will have high volume disease [6]. PDA reportedly
has a propensity to metastasize to the penis, testis, bone, liver, lungs,
and brain [2,4,5,8]. In 1991, Christensen et al. reported a study of 15
cases of PDA treated by radical prostatectomy, in which all of the pa-
tients appeared to have resectable disease. Final pathology revealed
large tumors, with a mean volume of 8.4 ml and involving a mean of
23% of the prostatic parenchyma. Extraprostatic spread was reported
in 93%, positive margins in 47%, and seminal vesicle involvement in
40% of the patients [3].
Studies have identiﬁed a gene rearrangement between the androgen
related gene TMPRSS2 and the transcription factor gene ERG which is
present in 40–60% of conventional acinar carcinoma of the prostate
[27–29]. A study by Lotan et al. showed the rate of the TMPRSS2-ERG
gene fusion to be less frequent in PDA as compared to conventional ac-
inar carcinoma (11% vs 45%). The signiﬁcantly lower rate of the gene fu-
sion in PDAemphasizes the fact that the genetic and biologic differences
between PDA and acinar carcinoma may be important in future thera-
peutic strategies [30].
In this patient, autopsy examination revealed nonbacterial throm-
botic endocarditis of the mitral valve and thromboemboli in the superi-
or mesenteric artery and bilateral renal arterial branches with
infarctions of the cerebrum, lung, small and large bowel, spleen, pros-
tate, and renal cortex. Malignancy is associated with a hypercoagulable
state and is major risk factor for thrombosis [31]. Certain malignancies,
particularly mucin-secreting adenocarcinomas of the ovary, pancreas,
stomach, and brain are associatedwith a higher risk of venous thrombo-
embolism (VTE) [32,33]. However, many nonmucin-producing tumors,
such as prostate carcinoma, are also associatedwith hypercoagulability.
In a study by Ording et al., the overall VTE rate was 2.8 times higher in
the prostate cancer cohort than in the general population [34]. Although
the incidence of VTE in prostate carcinoma is lower relative to mucin
producing tumors, due to the high prevalence of prostate carcinoma,
VTE in this patient population presents a major medical burden [35].
In a study by Nickel et al., the authors showed that prostate cancer
cells produce small vesicles (prostasomes) rich in polyphosphate that
promote thrombin generation via activation of coagulation factor XII
[36].
Nonbacterial thrombotic endocarditis (NBTE), formerly known as
marantic endocarditis, is characterized by sterile heart valve vegeta-
tions, consisting of ﬁbrin and platelet aggregates, in the absence of a
bacterial bloodstream infection. Recurrent emboli are a hallmark of
NBTE, occurring in up to 50% of patients, with a tendency to embolize
to the brain, kidney, spleen, mesenteric bed or the extremities [37].
The etiology of NBTE is thought to involve endothelial injury in the set-
ting of a hypercoagulable state. Endothelial damage caused by circulat-
ing cytokines (e.g., tumor necrosis factor, interleukin-1) in the presence
of a malignancy associated hypercoagulable state, may result in deposi-
tion of platelets and ﬁbrin upon heart valve leaﬂets [38]. One autopsy
series reported that, compared to the general population, patients
with underlying malignancy have a higher rate of NBTE (1.25% vs
0.2%). Higher rates of NBTE were reported in patients with adenocarci-
noma (e.g., lung, colon, ovary, biliary and prostate) (2.7% vs 0.47%) with
the highest rates observed in patients with pancreatic adenocarcinoma
(10.34%) [39].
3. Conclusion
PDA is an uncommon variant of prostate adenocarcinoma which is
histologically characterized by papillary or cribriform architecture
lined by tall columnar cells with abundant cytoplasm andpseudostratiﬁcation. PDA is associated with aggressive behavior with
an overall poor prognosis when compared to typical acinar prostate car-
cinoma. Metastatic PDA can be diagnostically challenging as papillary
and cribriform architecture can be found in metastatic carcinomas aris-
ing from many other organs [4]. Prostatic ductal adenocarcinoma
should be included in the differential diagnosis of a metastatic carcino-
ma showing papillary or cribriform architecture in middle-age to elder-
ly male patients.
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